CBD and THC are the two most recognized types of chemicals found in cannabis (marijuana). The aim of this study was to evaluate the safety and efficacy of CBD as an adjunctive treatment for seizures in patients with LGS.
LGS stands for Lennox-Gastaut syndrome, which is a severe developmental epileptic encephalopathy, and the current medications typically fail to control seizures in most patients.
Two trials involving 396 participants were performed comparing CBD to placebo. 40% of patients treated with CBD had a greater than 50% reduction of drop seizure frequency. 49% of the patients treated with CBD had a 50% or greater reduction in non-drop seizure frequency.
These are astounding results, considering that these were patients for whom currently approved anti epileptic drugs (AED’s) were not controlling their seizures.
CBD is a marijuana chemical that has a different mechanism of action than AED’s, and in this study was able to help 50% of those who had no help previously.
